Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
1,080 articles
Arbutus Biopharma Corporation $ABUS Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP reduced its holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS – Free Report) by 17.1% during the 3rd...
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP reduced its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 65.4% during the 3rd...
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP reduced its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 65.4% during the 3rd...
Gridiron Partners LLC Has $411,000 Stock Holdings in Eaton Vance Municipal Income Trust $EVN
Gridiron Partners LLC trimmed its position in Eaton Vance Municipal Income Trust (NYSE:EVN – Free Report) by 95.9% during the fourth quarter,...
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $761,676.24 in Stock
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 10,972 shares of the company’s stock in a transaction...
Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $801,588.00 in Stock
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 11,964 shares of the company’s stock in a transaction...
Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $801,639.57 in Stock
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) CEO Bobak Azamian sold 11,667 shares of the firm’s stock in a transaction...
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) CEO Sells $763,780.98 in Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) CEO Sean Mccarthy sold 118,969 shares of the business’s stock in a transaction...
IDEXX Laboratories, Inc. $IDXX Shares Sold by Grove Bank & Trust
Grove Bank & Trust lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 35.6% in the 4th quarter,...
IDEXX Laboratories, Inc. $IDXX Shares Sold by Grove Bank & Trust
Grove Bank & Trust lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 35.6% in the 4th quarter,...
Grove Bank & Trust Has $727,000 Holdings in Zoetis Inc. $ZTS
Grove Bank & Trust decreased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 65.6% during the 4th quarter, according to the...
Grove Bank & Trust Has $727,000 Holdings in Zoetis Inc. $ZTS
Grove Bank & Trust decreased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 65.6% during the 4th quarter, according to the...
Avior Wealth Management LLC Reduces Position in Eli Lilly and Company $LLY
Avior Wealth Management LLC reduced its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 11.8% during the fourth quarter, according...
Avior Wealth Management LLC Reduces Position in Eli Lilly and Company $LLY
Avior Wealth Management LLC reduced its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 11.8% during the fourth quarter, according...
Cyndeo Wealth Partners LLC Decreases Stock Position in Abbott Laboratories $ABT
Cyndeo Wealth Partners LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 8.8% in the fourth quarter,...
Cyndeo Wealth Partners LLC Decreases Stock Position in Abbott Laboratories $ABT
Cyndeo Wealth Partners LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 8.8% in the fourth quarter,...
CIBC Private Wealth Group LLC Reduces Stock Holdings in CVS Health Corporation $CVS
CIBC Private Wealth Group LLC cut its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 17.4% during the third quarter,...
CIBC Private Wealth Group LLC Reduces Stock Holdings in CVS Health Corporation $CVS
CIBC Private Wealth Group LLC cut its position in shares of CVS Health Corporation (NYSE:CVS – Free Report) by 17.4% during the third quarter,...
Groupama Asset Managment Sells 4,255 Shares of AptarGroup, Inc. $ATR
Groupama Asset Managment reduced its position in shares of AptarGroup, Inc. (NYSE:ATR – Free Report) by 70.4% in the third quarter, according...
Centene Corporation $CNC Shares Sold by Groupama Asset Managment
Groupama Asset Managment reduced its stake in Centene Corporation (NYSE:CNC – Free Report) by 70.5% during the 3rd quarter, according to the...
Centene Corporation $CNC Shares Sold by Groupama Asset Managment
Groupama Asset Managment reduced its stake in Centene Corporation (NYSE:CNC – Free Report) by 70.5% during the 3rd quarter, according to the...
Groupama Asset Managment Lowers Position in Jazz Pharmaceuticals PLC $JAZZ
Groupama Asset Managment decreased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 70.5% in the 3rd quarter,...
Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why
Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously...
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report)’s share price gapped down before the market opened on Friday . The...
Ambu A/S (OTCMKTS:AMBBY) Shares Gap Down – What’s Next?
Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at...
Eli Lilly and Company $LLY Stock Position Lessened by Abner Herrman & Brock LLC
Abner Herrman & Brock LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.7% during the fourth quarter,...
Eli Lilly and Company $LLY Stock Position Lessened by Abner Herrman & Brock LLC
Abner Herrman & Brock LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.7% during the fourth quarter,...
WELL Health Technologies (TSE:WELL) Stock Price Down 7.4% – What’s Next?
WELL Health Technologies Corp. (TSE:WELL – Get Free Report) shares traded down 7.4% during trading on Friday . The stock traded as low as...
Merit Medical Systems (NASDAQ:MMSI) Hits New 52-Week Low – Should You Sell?
Merit Medical Systems, Inc. (NASDAQ:MMSI – Get Free Report)’s share price reached a new 52-week low during trading on Friday . The stock...
Qiagen (NYSE:QGEN) Sets New 12-Month Low – Should You Sell?
Qiagen N.V. (NYSE:QGEN – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $39.85 and last traded...
SkinBioTherapeutics (LON:SBTX) Trading Down 34.6% – What’s Next?
SkinBioTherapeutics plc (LON:SBTX – Get Free Report) fell 34.6% on Friday . The stock traded as low as GBX 6.25 and last traded at GBX 6.28....
Scancell (LON:SCLP) Shares Down 3.1% – Here’s What Happened
Scancell Holdings plc (LON:SCLP – Get Free Report)’s stock price fell 3.1% on Friday . The company traded as low as GBX 11.63 and last...
Humana (NYSE:HUM) Reaches New 52-Week Low – Here’s What Happened
Humana Inc. (NYSE:HUM – Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $163.11 and...
Mark Cuban Says AI Revolution Is Easier For White Collar Workers Than PC Revolution, Predicts Job Cuts At Big Companies
Billionaire entrepreneur Mark Cuban took to X to weigh in on the ongoing AI revolution and its potential effects on the workforce.
AI Mirrors PC...
📰
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report.
📰
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Picard Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PMI
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p...
📰
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
📰
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
📰
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names....
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying The Motley Fool
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
2 Beaten-Down Stocks That Still Aren't Worth Buying
These stocks aren't nearly as cheap as they look.
📰
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway.